Unfolding like 100 years of home video footage that were shot by the family ghosts, Mascha Schilinski’s rich and mesmeric “ ...

Deep dive into RBAC vs ReBAC for enterprise sso. Learn which authorization model fits your ciam strategy and how to avoid role explosion in complex apps.

AI chipmaker Nvidia (NVDA) and pharmaceutical giant Eli Lilly (LLY) on Monday announced that the two companies would jointly invest $1 billion to create a lab in San Francisco focused on using AI to ...

Cosmologists are increasingly entertaining a radical possibility: that the cosmos might fold back on itself so that, on the ...

The Admiral Twin Drive-In in Tulsa stands as a magnificent time capsule where cinema magic meets starlit Oklahoma skies, creating an experience that will have you wondering why you waited so long to ...

The Admiral Twin Drive-In in Tulsa stands as a magnificent time capsule where cinema magic meets starlit Oklahoma skies, drawing movie lovers from Broken Arrow to Bartlesville and beyond. Remember ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

In October 1984 I arrived at Oxford University, trailing a large steamer trunk containing a couple of changes of clothing and about five dozen textbooks. I had a freshly minted bachelor’s degree in ...

Recursion Pharmaceuticals Inc has faced significant challenges in its financial performance, highlighted by a sharp decline in revenue growth, which fell to -32.98% in Q3 2025 from +30.14% in Q2 2025.